Rigel Pharmaceuticals (RIGL) investor relations material

Strategic growth and business development

• Four-pillar strategy focuses on commercial growth, in-licensing, pipeline advancement, and financial discipline, driving transformational growth since 2020.

• Transitioned from a single-product, negative cash position in 2020 to a profitable, three-product company by Q3 2024, with plans for four commercial products by the 2030s.

• Achieved a 32%-35% compound annual growth rate over the past five years, with significant revenue increases projected.

• In-licensed VEPPANU, a first-in-class FDA-approved PROTAC for metastatic breast cancer, expected to meaningfully expand the commercial portfolio.

• Business development targets differentiated, late-stage hematology and oncology assets synergistic with existing sales infrastructure.

Commercial performance and product portfolio

• Existing products TAVALISSE, GAVRETO, and REZLIDHIA showed strong year-over-year growth, with TAVALISSE and REZLIDHIA each growing 31%.

• International partnerships have expanded product availability in Europe, Japan, Canada, Israel, Brazil, and Mexico.

• VEPPANU is anticipated to become the largest revenue contributor, with launch targeted for August-September.

• The VEPPANU transaction includes $70 million upfront, $15 million for transition, up to $320 million in milestones, and tiered royalties.

• Pfizer and Arvinas retain clinical trial responsibilities, with up to $40 million contributed over four years.

Market opportunity and product differentiation

• VEPPANU addresses a 20,000-patient U.S. market for ER+/HER2-, ESR1-mutated metastatic breast cancer, a billion-dollar-plus opportunity.

• PROTAC mechanism offers a unique, repeatable protein degradation process, differentiating it from SERDs.

• Demonstrated 2.4-fold improvement in progression-free survival over fulvestrant and low rates of GI events and discontinuations.

• Real-world applicability confirmed, with launch readiness leveraging prior product launch experience.

• Sales force and distribution network positioned to maximize market impact.